Valuation: Alvotech

Market Cap 1.45B 1.25B 1.17B 1.07B 2.01B 138B 2.04B 13.74B 5.38B 69.33B 5.43B 5.32B 231B P/E 2026 *
15.3x
P/E 2027 * 8.85x
Enterprise Value 2.53B 2.18B 2.05B 1.87B 3.51B 242B 3.56B 24.03B 9.42B 121B 9.5B 9.3B 403B EV / Sales 2026 *
3.86x
EV / Sales 2027 * 3.21x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.86%
1 week+6.43%
Current month-1.58%
1 month+20.33%
3 months+22.51%
6 months-12.61%
Current year-20.96%
1 week 3.75
Extreme 3.75
4.18
1 month 3.04
Extreme 3.04
4.18
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.25
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 56 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Date Insider Type Main position Quantity % Market Cap.
2/26/26
Aztiq Pharma Partners SARL
BuyCompany 2,701,617 0.9038%
2/26/26 Buy

Founder

2,701,617 0.9038%
2/15/26 Sell

Founder

2,701,617 0.9038%
Change 5-day change 1-year change 3-year change Capi.($)
-4.56%+6.43%-49.47%-54.62% 1.45B
+0.68%-1.01%+2.16%+18.05% 48.42B
+4.07%+2.43%+481.62%+623.80% 43.66B
+4.33%+0.98%+13.53%+88.53% 39.51B
+1.94%-0.31%+25.29%+12.62% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
-0.44%-3.22% - - 16.32B
+3.22%-0.88%+28.99%+135.47% 16.15B
-0.62%+0.29%+3.46%+25.58% 14.16B
+2.35%+3.48%+82.60%+43.41% 13.37B
Average +1.42%+0.44%+67.64%+105.67% 26.46B
Weighted average by Cap. +1.93%-0.58%+100.19%+149.22%

Financials

2026 *2027 *
Net sales 656M 566M 531M 484M 910M 62.71B 922M 6.23B 2.44B 31.42B 2.46B 2.41B 105B 779M 673M 631M 575M 1.08B 74.48B 1.1B 7.4B 2.9B 37.32B 2.92B 2.86B 124B
Net income 91.8M 79.25M 74.35M 67.72M 127M 8.78B 129M 872M 342M 4.4B 345M 337M 14.63B 151M 131M 123M 112M 210M 14.47B 213M 1.44B 563M 7.25B 568M 556M 24.12B
Net Debt 1.08B 935M 877M 799M 1.5B 104B 1.52B 10.29B 4.03B 51.9B 4.07B 3.98B 173B 1.06B 912M 855M 779M 1.46B 101B 1.49B 10.03B 3.93B 50.59B 3.96B 3.88B 168B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-08-13 US$4.055 -0.86% 607,269
26-08-13 US$4.090 +2.00% 559,858
26-08-12 US$4.010 +5.53% 921,390
26-08-11 US$3.800 +0.80% 772,808
26-08-10 US$3.770 -1.05% 1,022,803
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.055USD
Average target price
5.750USD
Spread / Average Target
+41.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock